Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|March 22, 2008
Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experienceOmar S Din, Jason Lester, Alison Cameron, et al.
Trials|April 5, 2020
Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative studyAmanda Blatch-Jones, Jacqueline Nuttall, Abby Bull, et al.
British Journal of Cancer|August 18, 2018
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUSSimon Gollins, Nicholas West, David Sebag-Montefiore, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancerTamas Hickish, Jim Cassidy, David Propper, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2019
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapySiow Ming Lee, Sunil Upadhyay, Conrad Lewanski, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinomaAnne Thomas, Pradeep S Virdee, Martin Eatock, et al.
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic CancerChristopher N Hurt, Somnath Mukherjee, John Bridgewater, et al.
The Lancet. Gastroenterology & Hepatology|December 20, 2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialRichard Adams, Ewan Brown, Louise Brown, et al.
The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.
The Lancet. Oncology|March 12, 2013
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trialSomnath Mukherjee, Christopher N Hurt, John Bridgewater, et al.
Pageof 6